After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.
Due to Imitrex's commercial success, GSK is the current migraine market leader. Trexima, co-developed by GSK and Pozen represents GSK's product line extension for its migraine franchise, but approval delays and the impending US sumatriptan patent expiry will limit its success.
Newer news items
|< Prev||Next >|
Monitoring Downloads Section
You can easily monitor all new articles and reports published at Downloads Section of Farmavita.Net. Click on the RSS button and bookmark this RSS feed. RSS button is located beside title “Farmavita.Net - Pharmaceutical Licensing Network :: File Repository“.